Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. This is...
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore...
Goals 0.71, 0.63. Invalidation at 1.02 . We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that...
Phio Pharmaceuticals Corp (NASDAQ:PHIO) was one of the biggest winners on Friday as the stock closed up $1.44 on the day with huge volumes. I alerted it when it was trading at 75c as a potential big mover due to its huge cash position and catalyst and it did not disappoint us. Looking at the technical daily chart the near-term outlook is very positive, with...
Pupm&Dump trading strategy idea. $PHIO is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,34; stop-loss — $2,50; take-profit — $2,02/MOC Do not view this idea as a recommendation for trading or investing. It is...
Pupm&Dump trading strategy idea. $PHIO is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,75; stop-loss — $3,19; take-profit — $2,31; Do not view this idea as a recommendation for trading or...
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.